Pulse Biosciences Inc
NASDAQ:PLSE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.66
24.56
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Operating Margin
Pulse Biosciences Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Pulse Biosciences Inc
NASDAQ:PLSE
|
1B USD |
-91 799%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
217.7B USD |
18%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
207.9B USD |
29%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
142.9B USD |
19%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
136.3B USD |
22%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
125.3B USD |
19%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
50.2B EUR |
14%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
56.2B USD |
16%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
56.2B USD |
31%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
50.2B USD |
28%
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
38.2B USD |
14%
|
Pulse Biosciences Inc
Glance View
Pulse Biosciences Inc. operates at the intriguing intersection of healthcare innovation and cutting-edge technology, focusing on the development and commercialization of their proprietary Nano-Pulse Stimulation (NPS) technology. NPS is a novel bio-electrical platform designed to deliver ultra-short electrical pulses designed to induce cell stress and modify cell structure without significantly impacting non-cellular structural elements. The company primarily concentrates on medical applications that demand precision and safety, notably in dermatology, oncology, and other critical therapeutic areas. By developing devices like the CellFX System, Pulse Biosciences allows physicians to treat conditions with minimal invasiveness, offering alternatives to traditional methods like surgery. Pulse Biosciences generates revenue by selling these medical devices and fostering strategic partnerships within the healthcare sector to expand the application and adoption of NPS technology. The company's business model hinges on convincing healthcare professionals and institutions of the tangible benefits and potential cost savings that their innovative solutions offer. By aligning themselves with clinicians and medical researchers, Pulse Biosciences endeavors to expand the clinical indications for NPS technology, gradually scaling their market presence. Although the journey involves navigating the complex regulatory landscape and proof of clinical efficacy, the company aims to sustain growth through continuous innovation and market expansion, targeting widespread adoption of their groundbreaking platforms.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Pulse Biosciences Inc's most recent financial statements, the company has Operating Margin of -91 798.8%.